Figure 1From: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen® Concentration-dependent inhibition of [ 125 I]-G-CSF binding by BK0023 (black circle) and Neupogen ® (open circle) in NFS-60 cells expressing G-CSF receptor. Data are reported as percent of specific binding at each concentration of displacer and are the means ± S.E.M. of four separate experiments. Statistical analysis by Student’s t-test did not show any significant difference between BK0023 and Neupogen®.Back to article page